Aquavit Pharmaceuticals Launches First-of-its-kind AQUAGOLD® Fine Touch™
Aquavit Pharmaceuticals, Inc. has introduced an innovative technology called AQUAGOLD® fine touch™, revolutionizing direct dermal applications.
The standout feature of AQUAGOLD® fine touch™ is its ability to minimize the risk of discomfort and swelling on the facial skin, making it particularly suitable for treating areas such as the mouth and eyes. These challenging regions are traditionally difficult to address using existing delivery methods available in the market.
This groundbreaking technology addresses long-standing unmet needs in both the medical aesthetics market, valued at over 11 billion dollars, and the vitamin and mineral market, estimated at 30 billion dollars.
Dr. David Shafer, Chief Medical Technology Officer of Aquavit Pharmaceuticals, highlights that AQUAGOLD® fine touch™ can be used in response to patients' increasing demands. It is compatible with microbotox, hyaluronic acid-based fillers, and vitamin combinations, providing a versatile solution for various treatment options.
